Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Calidi Biotherapeutics ( (CLDI) ) has issued an update.
Calidi Biotherapeutics, Inc. announced the elimination of the position of President, Medical and Scientific Affairs, previously held by Dr. Boris Minev, effective July 29, 2025. Following this decision, a Separation Agreement was executed with Dr. Minev on August 8, 2025, which includes a general release of claims and outlines financial compensations, including a $100,000 bonus and $187,500 in separation pay, along with COBRA premium payments for six months.
The most recent analyst rating on (CLDI) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Calidi Biotherapeutics stock, see the CLDI Stock Forecast page.
Spark’s Take on CLDI Stock
According to Spark, TipRanks’ AI Analyst, CLDI is a Underperform.
Calidi Biotherapeutics’ overall stock score reflects significant financial and technical challenges, typical of a developing biotech company. While corporate events bring positive leadership changes and strategic advancements, the company’s lack of revenue, high leverage, and bearish technical indicators weigh heavily on its score.
To see Spark’s full report on CLDI stock, click here.
More about Calidi Biotherapeutics
Average Trading Volume: 1,465,981
Technical Sentiment Signal: Sell
Current Market Cap: $15.22M
See more data about CLDI stock on TipRanks’ Stock Analysis page.